1. Salimi A, Pourahmad J. Measurement of Mitochondrial Toxicity Parameters in Embryonic Hippocampus.Methods Mol Biol. 2018;1797:537-44.
  2. Patananan AN, Sercel AJ, Teitell MA. More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol. 2018 ;3:16-24.
  3. Thar R, Kühl M. Propagation of electromagnetic radiation in mitochondria? J Theoretical Biology. 2004;230(2):261-70.
  4. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017-28.
  5. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007;292(1):C33-44.
  6. Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018 Jun 11. pii: S0140-6736(18)30727-X. doi: 10.1016/S0140-6736(18)30727-X. [Epub ahead of print]
  7. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol. 2013;61(6):599-610.
  8. Chen M, Liu B, Gao Q, Zhuo Y, Ge J. Mitochondria-targeted peptide MTP-131 alleviates mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(10):7027-37.
  9. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res. 2011;8(4):393-409.
  10. Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45(1):4-16.
  11. Suomalainen A, Battersby BJ. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol. 2018;19(2):77-92.
  12. Ahuja AS. Understanding mitochondrial myopathies: a review. PeerJ. 2018;6:e4790.
  13. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221
  14. Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22: 1041-52.
  15. Siegel M, Kruse S, Percival J, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetic and skeletal muscle performance in aged mice. Aging Cell. 2013;12:763-771.
  16. Birk A, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 reenergizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250-61.
  17. Brown DA, Hale SL, Baines CP, et al. Reduction of early reperfusion injury with the mitochondria-targeting peptide Bendavia. J Cardiovasc Pharmacol. 2014;19:121-32.
  18. Stauffer B, Sparagna G, Chau S, et al. MTP131, a cardiolipin targeting peptide,improves mitochondrial activity in the failing human heart. Eur J Heart Fail Abstr Suppl 2016;18:289.
  19. Eirin A, Ebrahimi B, Zhang X, et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res. 2014;103: 461-72.
  20. Gorman et. al. ANN NEUROL 2015;77:753–759.
  21. MMPOWER-3 Clinical Trial Information. Available at Accessed June 21, 2018.
  22. Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M, et al. The Barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study. Am J Med Genet A. 2012;158A:2726-32.
  23. Wortmann SB, Kluijtmans LA, Engelke UF, Wevers RA, Morava E. The 3-methylglutaconic acidurias: what’s new? J Inherit Metab Dis. 2012;35(1):13-22.
  24. Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. Barth syndrome. Orphanet J Rare Dis. 2013;8:23.
  25. TAZPOWER Clinical Trial Information. Available at Accessed June 21, 2018.
  26. Jurkute N, Yu-Wai-Man P. Leber hereditary optic neuropathy: bridging the translational gap. Curr Opin Ophthalmol. 2017;28(5):403-09.
  27. LHON Global. How rare is LOHN? Page updated September 2015. Accessed June 16, 2018 at
  28. Ratican SE, Osborne A, Martin KR. Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber’s Hereditary Optic Neuropathy. Neural Plast. 2018;2018:7108948.
  29. ReSIGHT Clincal Trial Information. Available at Accessed June 21, 2018.
  30. Ratnapriya R, Chew EY. Age-related macular degeneration-clinical review and genetics update. Clin Genet. 2013;84(2):160-6.
  31. Hernández-Zimbrón LF, Zamora-Alvarado R, Ochoa-De la Paz L, Velez-Montoya R, Zenteno E, Gulias-Cañizo R, et al. Age-related macular degeneration: new paradigms for treatment and management of AMD. Oxid Med Cell Longev. 2018;2018:8374647
  32. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, TY Wong. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2: e106–16.
  33. Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Opthalmol. 2004;122(4):477-85.
  34. ReCLAIM Clincial Trial Information. Available at Accessed June 21, 2018.
  35. Chinnery PF. Mitochondrial Disorders Overview. 2000 Jun 8 [Updated 2014 Aug 14]. Available from: Accessed June 16, 2018.
  36. Noble P. “Denis Archibald Leigh”. Psychiatric Bulletin. 2018;22 (10):648-9.
  37. Barth PG, Scholte HR, Berden JA, Vanderkleivanmoorsel JM, Luythouwen IEM, Vantveerkorthof ET, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci. 1983;62: 327-55.
  38. Brown, Lewin, and Ash; Retinal Degenerative Diseases, Advances in Experimental Medicine and Biology 891,
  39. Arbustini et al. Cardiac Phenotypes in Hereditary Muscle Disorders. JACC 2018
  40. Burelle et al., Alterations in mitochondrial function as a harbinger of cardiomyopathy: Lessons from the dystrophic heart. JMCC 2009